TrialSignal transduction and targeted therapy2023

Toripalimab combined with lenvatinib and GEMOX is a promising regimen as first-line treatment for advanced intrahepatic cholangiocarcinoma: a single-center, single-arm, phase 2 study.

Guo-Ming Shi et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.